Supriya Lifescience Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors also recommended a final dividend of Re. 1.00 per equity share (50% on a face value of Rs. 2/- each), subject to shareholder approval at the ensuing Annual General Meeting. The company’s revenue from operations for the quarter ended March 31, 2026, stood at 2,765.28 million, compared to 2,064.40 million in the previous quarter and 1,841.09 million in the corresponding quarter of the previous year. Profit for the period was 742.29 million for the quarter ended March 31, 2026, compared to 496.75 million in the previous quarter and 503.82 million in the corresponding quarter of the previous year.

Supriya Lifescience Limited is a prominent Indian manufacturer of Active Pharmaceutical Ingredients (APIs) with a strong global footprint. The company specializes in producing niche products across various therapeutic segments, including antihistamines, analgesics, and anaesthetics. During 2025, the company focused on expanding its manufacturing capabilities and strengthening its regulatory compliance framework to bolster its export-oriented business model. As of the end of the 2026 financial year, the company reported no subsidiary, associate, or joint venture entities.